A new pre-clinical study shows that stem cell-derived conditioned medium (iPSC-CM)—the liquid remaining after stem cells are cultured—reduces signs of pulmonary arterial hypertension in rat and cell models.
In pulmonary arterial hypertension rats treated with daily iPSC-CM infusions, researchers observed reduced blood pressure in the right ventricle, decreased heart enlargement, and thinner pulmonary arterial walls. At the molecular level, the treatment lowered key drivers of blood vessel remodeling and reduced oxidative stress.
The findings, published in the Journal of Cellular Physiology, suggest iPSC-CM is a promising cell-free therapeutic approach for pulmonary arterial hypertension. Researchers call for further studies on scalability, manufacturing, and delivery methods before clinical application.
Read more at this link on Pulmonary Hypertension News, original article here